u/Freedom5567

People are starting to miss the bigger picture here.

Look at what is already being shown with REYOBIQ.

For recurrent GBM, historical therapies such as bevacizumab based approaches have often shown median overall survival in roughly the 7 to 10 month range, while PSTV has already reported approximately 17 months median overall survival in patients receiving ≥100 Gy. That is approaching 2x historical survival ranges and is not something you casually ignore.

Now look at LM.

LM is one of the most devastating CNS conditions with historical survival often around 2 to 6 months, and PSTV has already reported approximately 9 months median overall survival at the recommended Phase 2 dose. Depending on the comparison used, that represents a meaningful improvement versus historical outcomes.

And here is the part many seem to overlook…

This is not even including the ongoing Phase 2 strategy involving multiple doses.

The GBM data discussed above came from earlier findings, and LM has moved into a multidose design intended to optimize therapeutic exposure. Nobody can claim improved survival yet because the data still has to mature, but if increased and sustained exposure translates into better outcomes, the upside becomes very interesting.

Then add everything else around it:

CNSide reimbursement progress

Medicare enrollment progress

Manufacturing scale up already underway

FDA discussions involving overall survival and accelerated approval pathways

Diagnostics and therapeutics under one roof

At some point the discussion changes from “Can PSTV survive?” to “How big can PSTV become if the data continues holding up?”

Not financial advice. Just connecting publicly available information.

TLDR: REYOBIQ is showing about 17 month survival in recurrent Glioblastoma, outperforming current drugs like Bevacizumab and Lomustine while approaching frontline outcomes. That is not something you typically see in this setting.

I wanted to compare REYOBIQ directly against current treatments for Glioblastoma because there are already established options, and I wanted to understand what actually makes this different.

After digging into the data, I was honestly surprised by how limited outcomes still are with the therapies we have today.

Standard of care with surgery, radiation, and Temozolomide gives around 14 to 18 months in newly diagnosed patients. Add Optune and you might push that closer to 20 months, but that is still frontline.

Once it recurs, which it almost always does, things drop off fast. Most patients end up on Bevacizumab or Lomustine, and survival is typically just 6 to 9 months.

That is the reality today.

Now compare that to REYOBIQ.

In the higher dose group, patients are showing around 17 months overall survival in recurrent GBM.

That is the part that stands out.

You are looking at survival that is approaching, and in some cases matching, frontline outcomes, but in a much tougher recurrent setting where current treatments struggle to reach even half of that.

The fact that it is already outperforming current recurrent GBM treatments like Bevacizumab and Lomustine is what makes this signal so important.

And it is not just a random spike. The data shows a dose response. Higher absorbed radiation is translating into longer survival, which is exactly what you would expect if the treatment is working.

It is still early and needs to hold, but this is not the kind of signal you typically see unless something real is happening.

At the end of the day, beyond all the data and comparisons, this is really about patients.

For people facing Glioblastoma, the outlook today is incredibly difficult, and options are limited.

If REYOBIQ continues to show what it has so far, it has the potential to give patients something they rarely get in this setting meaningful time and a real chance at a better outcome.

I personally found this to be quite compelling and felt it was worth sharing.